Drugs / Tremelimumab
Tremelimumab
also known as
CP-675,206 · Ticilimumab · Bacille Calmette-Guérin (BCG) · Imjudo · treme · BCG vaccine · CP-675
Monoclonal antibody targets CTLA4 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Imjudo | — | 2023-02-20 | europa.eu ↗ |
Trials 247 · started per year
today
EU approved 2023
1
2
1
6
3
4
3
2
2
5
10
18
28
43
35
15
13
8
9
9
8
13
8
20032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 06 trials | ||||||
| Phase 0 | NCT06824363 | May 2026 → Jan 2027 expected | esophageal adenocarcinoma, gastric adenocarcinoma | University of California, Irvine | Recruiting | No outcome recorded |
| Phase 0 | NCT04223648 | Aug 2020 → Feb 2022 | melanoma | Yale University | Withdrawn | No outcome recorded |
| Phase 0 | NCT04005690 | Aug 2019 → Jun 2026 overdue | pancreatic ductal adenocarcinoma | OHSU Knight Cancer Institute | Recruiting | No outcome recorded |
| Phase 0 | NCT03132467 | Jun 2017 → Jan 2019 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, progesterone-receptor positive breast cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT02812420 | Mar 2017 → Dec 2027 expected | hydronephrosis, infiltrating bladder urothelial carcinoma sarcomatoid variant, kidney pelvis sarcomatoid transitional cell carcinoma, micropapillary variant infiltrating bladder urothelial carcinoma +3 | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT02626130 | Mar 2016 → Jun 2022 | clear cell renal carcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 155 trials | ||||||
| Phase 1 | NCT06564623 | May 2025 → Mar 2029 expected | biliary tract cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 1 | NCT06710223 | Jan 2025 → Jun 2027 expected | hepatocellular carcinoma | University of California, San Diego | Recruiting | No outcome recorded |
| Phase 1 | NCT06058663 | Jun 2024 → Nov 2026 expected | intrahepatic cholangiocarcinoma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 1 | NCT05701488 | Apr 2023 → Oct 2026 expected | hepatocellular carcinoma | Jiping Wang, MD, PhD | Recruiting | No outcome recorded |
| Phase 1 | NCT05928962 | Oct 2022 → Aug 2023 | melanoma | Fujian Cancer Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT04605731 | Aug 2021 → Feb 2027 expected | hepatocellular carcinoma | City of Hope Medical Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03963414 | Sep 2020 → Dec 2021 | small cell lung carcinoma | University of Nebraska | Terminated | No outcome recorded |
| Phase 1 | NCT04073160 | Jun 2020 → Jul 2021 | urinary bladder cancer | Daniel George, MD | Withdrawn | No outcome recorded |
| Phase 1 | NCT03802747 | Aug 2019 → Dec 2023 | colorectal cancer | University of Colorado, Denver | Withdrawn | No outcome recorded |
| Phase 1 | NCT03923270 | Jun 2019 → Jun 2023 overdue | small cell lung carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04287894 | Dec 2018 → Nov 2024 | non-small cell lung carcinoma | The Netherlands Cancer Institute | Terminated | No outcome recorded |
| Phase 1 | NCT03452332 | Jul 2018 → Aug 2023 | cervical adenocarcinoma, cervical squamous cell carcinoma, vaginal adenocarcinoma, vaginal squamous cell carcinoma +2 | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT03277482 | Jun 2018 → Jul 2022 | cervical carcinoma, endometrial cancer, ovarian carcinoma, vaginal cancer +1 | Dana-Farber Cancer Institute | Terminated | No outcome recorded |
| Phase 1 | NCT03509012 | May 2018 → Dec 2020 | head and neck squamous cell carcinoma, non-small cell lung carcinoma, small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT03275597 | Feb 2018 → Jul 2020 | non-small cell lung carcinoma | University of Wisconsin, Madison | Terminated | No outcome recorded |
| Phase 1 | NCT03085849 | Dec 2017 → Nov 2018 | small cell lung carcinoma | Catherine Shu | Completed | No outcome recorded |
| Phase 1 | NCT03144778 | Jul 2017 → Mar 2021 | oropharynx squamous cell carcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT03005002 | Jun 2017 → Nov 2019 | Lynch syndrome 1, Lynch syndrome 4, Lynch syndrome 5, metastatic carcinoma | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT03122496 | Apr 2017 → Jun 2022 | thyroid gland undifferentiated (anaplastic) carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT03089645 | Mar 2017 → Jun 2020 | cancer | MedImmune LLC | Completed | No outcome recorded |
| Phase 1 | NCT03019003 | Mar 2017 → Sep 2024 | head and neck cancer | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02762006 | Dec 2016 → Nov 2020 | renal cell carcinoma | Moshe Ornstein | Completed | No outcome recorded |
| Phase 1 | NCT02716805 | Dec 2016 → Feb 2018 | plasma cell myeloma | Ludwig Institute for Cancer Research | Terminated | No outcome recorded |
| Phase 1 | NCT02978482 | Dec 2016 → Jan 2018 | cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02754856 | Aug 2016 → Jan 2023 | colorectal cancer, metastatic carcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT02868632 | Aug 2016 → Mar 2019 | malignant pancreatic neoplasm | NYU Langone Health | Withdrawn | No outcome recorded |
| Phase 1 | NCT02549651 | Jul 2016 → Feb 2019 | diffuse large B-cell lymphoma | MedImmune LLC | Completed | No outcome recorded |
| Phase 1 | NCT02718911 | Jun 2016 → Dec 2018 | cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02658214 | Apr 2016 → Nov 2019 | esophageal squamous cell carcinoma, fallopian tube neoplasm, gastric neoplasm, gastroesophageal cancer +6 | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02705482 | Mar 2016 → Aug 2019 | cancer | MedImmune LLC | Completed | No outcome recorded |
| Phase 1 | NCT02639026 | Jan 2016 → Jun 2023 | breast cancer, malignant pancreatic neoplasm, melanoma, metastatic malignant neoplasm +1 | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 1 | NCT02485990 | Jan 2016 → Mar 2020 | primary peritoneal carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded |
| Phase 1 | NCT02616185 | Dec 2015 → Feb 2021 | prostate neoplasm | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT02586987 | Dec 2015 → Jul 2018 | biliary tract cancer, breast cancer, colorectal cancer, gastroesophageal cancer +4 | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02537418 | Oct 2015 → Jul 2018 overdue | cancer | Canadian Cancer Trials Group | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02301130 | Nov 2014 → Dec 2017 | cancer | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02262741 | Oct 2014 → Sep 2017 | head and neck squamous cell carcinoma | MedImmune LLC | Completed | No outcome recorded |
| Phase 1 | NCT02261220 | Oct 2014 → Jan 2020 | cancer | MedImmune LLC | Completed | No outcome recorded |
| Phase 1 | NCT02141347 | May 2014 → Jan 2017 | malignant mesothelioma | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02117219 | May 2014 → Apr 2019 | myelodysplastic syndrome | MedImmune LLC | Completed | No outcome recorded |
| Phase 1 | NCT02141542 | May 2014 → Sep 2020 | metastatic melanoma | F. Stephen Hodi, MD | Completed | No outcome recorded |
| Phase 1 | NCT02040064 | Jan 2014 → Mar 2016 | non-small cell lung carcinoma | Gustave Roussy, Cancer Campus, Grand Paris | Completed | No outcome recorded |
| Phase 1 | NCT01975831 | Dec 2013 → Dec 2019 | breast cancer, cervical cancer, colorectal cancer, ovarian cancer +1 | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase 1 | NCT02000947 | Oct 2013 → Sep 2019 | non-small cell lung carcinoma | MedImmune LLC | Completed | No outcome recorded |
| Phase 1 | NCT01938612 | Sep 2013 → Mar 2018 | cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04274816 | Jul 2012 → Feb 2014 | cutaneous melanoma | A.J.M. van den Eertwegh | Completed | No outcome recorded |
| Phase 1 | NCT01334099 | Jul 2010 → Mar 2013 | breast cancer | University Health Network, Toronto | Terminated | No outcome recorded |
| Phase 1 | NCT01103635 | Feb 2010 → May 2016 | metastatic melanoma | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 1 | NCT00880854 | Jun 2009 → Feb 2011 | urinary bladder cancer | University of Wisconsin, Madison | Withdrawn | No outcome recorded |
| Phase 1 | NCT00702923 | Jul 2008 → Sep 2011 | prostate cancer | University of Wisconsin, Madison | Terminated | No outcome recorded |
| Phase 1 | NCT00556023 | Jun 2008 → Aug 2011 | malignant pancreatic neoplasm | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00585000 | Dec 2007 → Jan 2010 | melanoma | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT00372853 | Nov 2006 → May 2010 | renal cell carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00431275 | Jun 2006 → Feb 2008 | melanoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00090896 | Apr 2004 → Jul 2008 | cutaneous melanoma | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1/234 trials | ||||||
| Phase 1/2 | NCT06608940 | Nov 2025 → Jan 2027 | hepatocellular carcinoma | Case Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT06911255 | Apr 2025 → Mar 2028 expected | hepatocellular carcinoma | Yoon Jun Kim | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05932199 | Jul 2024 → May 2028 expected | mesothelioma | Baylor College of Medicine | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04989218 | Jan 2023 → Mar 2024 | cholangiocarcinoma | University of Alabama at Birmingham | Terminated | No outcome recorded |
| Phase 1/2 | NCT05120622 | Sep 2021 → May 2022 | bladder carcinoma in situ | University of British Columbia | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03871036 | May 2019 → Sep 2023 | urothelial carcinoma | The Netherlands Cancer Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT03581487 | Apr 2019 → Oct 2025 | non-small cell lung carcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT03837899 | Mar 2019 → Feb 2023 overdue | childhood malignant neoplasm, hematopoietic and lymphoid cell neoplasm | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03549715 | Dec 2018 → Jun 2024 | infiltrating bladder urothelial carcinoma | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | Unknown | No outcome recorded |
| Phase 1/2 | NCT03693612 | Nov 2018 → Jun 2021 | neoplasm | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/2 | NCT03539822 | Oct 2018 → Jun 2028 expected | colorectal cancer, esophageal adenocarcinoma, gastric cancer, hepatocellular carcinoma | Anwaar Saeed | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03618134 | Oct 2018 → Jun 2023 | human papilloma virus infection, oropharynx squamous cell carcinoma | Jonsson Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT03784066 | Aug 2018 → Mar 2025 overdue | oral cavity squamous cell carcinoma | Universitaire Ziekenhuizen KU Leuven | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03283605 | Jul 2018 → Jul 2024 | head and neck squamous cell carcinoma | University of Montreal Hospital Centre (CHUM) | Unknown | No outcome recorded |
| Phase 1/2 | NCT03518606 | Jun 2018 → Apr 2022 | breast cancer, cervical cancer, head and neck cancer, prostate cancer | UNICANCER | Completed | No outcome recorded |
| Phase 1/2 | NCT03751761 | Jun 2018 → Aug 2023 | gastric cancer | Asan Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT03522584 | May 2018 → Dec 2021 | head and neck squamous cell carcinoma | University of Washington | Terminated | No outcome recorded |
| Phase 1/2 | NCT03164772 | Dec 2017 → Oct 2021 | non-small cell lung carcinoma | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase 1/2 | NCT03206073 | Dec 2017 → Sep 2020 | colorectal adenocarcinoma, refractory malignant neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT03317158 | Nov 2017 → Dec 2028 expected | urinary bladder cancer, urothelial carcinoma | Noah Hahn, M.D. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03249142 | Oct 2017 → Dec 2024 | ovarian cancer | ARCAGY/ GINECO GROUP | Completed | No outcome recorded |
| Phase 1/2 | NCT03202758 | Aug 2017 → Jan 2023 | colorectal cancer | Centre Georges Francois Leclerc | Completed | No outcome recorded |
| Phase 1/2 | NCT03116529 | Jun 2017 → Jun 2024 | soft tissue sarcoma | University of Maryland, Baltimore | Terminated | No outcome recorded |
| Phase 1/2 | NCT03212469 | Jun 2017 → Feb 2025 | esophageal cancer, head and neck squamous cell carcinoma, lung cancer | Gustave Roussy, Cancer Campus, Grand Paris | Completed | No outcome recorded |
| Phase 1/2 | NCT02643303 | Dec 2016 → Feb 2022 | breast cancer, cutaneous neuroendocrine carcinoma, head and neck squamous cell carcinoma, kidney cancer +6 | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase 1/2 | NCT02962063 | Nov 2016 → Nov 2026 expected | esophageal adenocarcinoma, gastroesophageal junction adenocarcinoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02735239 | Jun 2016 → Jun 2022 | esophageal cancer | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase 1/2 | NCT02571725 | Feb 2016 → Dec 2020 overdue | fallopian tube cancer, ovarian cancer, peritoneal neoplasm | New Mexico Cancer Research Alliance | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02499328 | Aug 2015 → Feb 2020 | head and neck squamous cell carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1/2 | NCT02340975 | Mar 2015 → Apr 2019 | adenocarcinoma | MedImmune LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT02311361 | Mar 2015 → Oct 2019 | malignant pancreatic neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT02205333 | Aug 2014 → Apr 2016 | aggressive B-cell non-Hodgkin lymphoma, cancer | MedImmune LLC | Terminated | No outcome recorded |
| Phase 1/2 | NCT01853618 | May 2013 → Jun 2017 | biliary tract cancer, hepatocellular carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00075192 | Mar 2004 → Mar 2006 | prostate neoplasm | AstraZeneca | Completed | No outcome recorded |
| Phase 2124 trials | ||||||
| Phase 2 | NCT06855225 | Jul 2026 → May 2027 expected | combined hepatocellular carcinoma and cholangiocarcinoma | Mehmet Akce | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07288034 | Apr 2026 → Oct 2028 expected | non-small cell lung carcinoma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07511504 | Apr 2026 → Aug 2027 expected | hepatocellular carcinoma | OHSU Knight Cancer Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07489976 | Apr 2026 → Apr 2030 expected | hepatocellular carcinoma | Ju Dong Yang | Recruiting | No outcome recorded |
| Phase 2 | NCT07122089 | Feb 2026 → Jan 2030 expected | hepatocellular carcinoma | Center Eugene Marquis | Recruiting | No outcome recorded |
| Phase 2 | NCT07174570 | Jan → Nov 2026 expected | hepatocellular carcinoma | Emory University | Recruiting | No outcome recorded |
| Phase 2 | NCT06994299 | Oct 2025 → Jul 2027 | hepatocellular carcinoma | Weill Medical College of Cornell University | Withdrawn | No outcome recorded |
| Phase 2 | NCT07168668 | Sep 2025 → May 2028 expected | hepatocellular carcinoma | Chang Gung Memorial Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07081633 | Aug 2025 → Nov 2026 expected | hepatocellular carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06999707 | May 2025 → May 2030 expected | hepatocellular carcinoma | Chang Gung Memorial Hospital | Recruiting | No outcome recorded |
| Show all 124 trials opens the full record — a long page | ||||||
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06904170 | Nov 2025 → Sep 2029 expected | hepatocellular carcinoma | UNICANCER | Recruiting | No outcome recorded |
| Phase 323 trials | ||||||
| Phase 3 | NCT07166406 | Feb 2026 → Mar 2029 expected | hepatocellular carcinoma | NRG Oncology | Recruiting | No outcome recorded |
| Phase 3 | NCT06841172 | Jul 2025 → Jul 2027 expected | hepatocellular carcinoma | Shandong Cancer Hospital and Institute | Recruiting | No outcome recorded |
| Phase 3 | NCT07027436 | Jul 2025 → Oct 2027 expected | hepatocellular carcinoma | Hamilton Health Sciences Corporation | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06921785 | May 2025 → Mar 2029 expected | hepatocellular carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT05557838 | Feb 2023 → Sep 2026 expected | hepatocellular carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05301842 | Mar 2022 → Feb 2026 overdue | hepatocellular carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04585490 | Aug 2021 → Aug 2026 overdue | non-small cell lung carcinoma | Maximilian Diehn | Recruiting | No outcome recorded |
| Phase 3 | NCT04960709 | Aug 2021 → Mar 2026 overdue | urinary bladder carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04379336 | May 2020 → Jan 2022 | COVID-19 | TASK Applied Science | Completed | No outcome recorded |
| Phase 3 | NCT03703297 | Sep 2018 → Jan 2024 overdue | small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03682068 | Sep 2018 → Jun 2026 overdue | urothelial carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03288532 | Jul 2018 → Jul 2024 overdue | renal cell carcinoma | University College, London | Recruiting | No outcome recorded |
| Phase 3 | NCT03298451 | Oct 2017 → Aug 2021 overdue | hepatocellular carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03084471 | Jun 2017 → Mar 2020 | high grade malignant neoplasm | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT03164616 | Jun 2017 → Mar 2021 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03043872 | Mar 2017 → Jan 2020 overdue | small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02542293 | Nov 2015 → Sep 2020 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02516241 | Nov 2015 → Jan 2020 overdue | urothelial carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02551159 | Oct 2015 → Jul 2020 | head and neck squamous cell carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02369874 | Sep 2015 → Sep 2018 | head and neck squamous cell carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02453282 | Jul 2015 → Oct 2018 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02352948 | Jan 2015 → Feb 2018 | non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00257205 | Mar 2006 → Aug 2010 | melanoma | AstraZeneca | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04537663 | Sep 2020 → Jul 2021 | COVID-19, respiratory tract infectious disorder | UMC Utrecht | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02563925 | Sep 2015 → Jul 2021 | breast cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase not stated2 trials | ||||||
| — | NCT00584493 | May 2008 → ? | — | Pfizer | No longer available | No outcome recorded |
| — | NCT05345678 | — | hepatocellular carcinoma | AstraZeneca | Approved for marketing | No outcome recorded |
Also used as a comparator or background therapy in 14 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07391670 Background | Mar 2026 → Aug 2027 expected | cancer | AstraZeneca | Recruiting | No outcome recorded |
| Phase 211 trials | ||||||
| Phase 2 | NCT07175441 Comparator | Apr 2026 → Apr 2027 expected | hepatocellular carcinoma | Riboscience, LLC. | Recruiting | No outcome recorded |
| Phase 2 | NCT06880523 Background | Oct 2025 → Jan 2028 expected | hepatocellular carcinoma | Canadian Cancer Trials Group | Recruiting | No outcome recorded |
| Phase 2 | NCT05451043 Background | Jul 2023 → Oct 2026 expected | cholangiocarcinoma, hepatocellular carcinoma, malignant pancreatic neoplasm | AHS Cancer Control Alberta | Recruiting | No outcome recorded |
| Phase 2 | NCT03606967 Background | Apr 2021 → Dec 2026 expected | invasive breast carcinoma, triple-negative breast carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT04221555 Comparator | May 2020 → Apr 2025 | adenocarcinoma | Asan Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT03847649 Comparator | Mar 2020 → Apr 2030 expected | cancer | Canadian Cancer Trials Group | Recruiting | No outcome recorded |
| Phase 2 | NCT03737968 Comparator | Jan 2019 → Oct 2023 | hypopharyngeal carcinoma, oral cavity squamous cell carcinoma, oropharyngeal carcinoma | Yonsei University | Unknown | No outcome recorded |
| Phase 2 | NCT03994393 Comparator | Oct 2018 → Jun 2023 | lung cancer | University of Sydney | Unknown | No outcome recorded |
| Phase 2 | NCT03057106 Comparator | Mar 2017 → Feb 2020 overdue | lung cancer | Canadian Cancer Trials Group | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02592551 Comparator | May 2016 → Aug 2019 | mesothelioma | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT00378482 Background | Mar 2007 → Oct 2023 | colorectal neoplasm, melanoma, prostate neoplasm, renal cell carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06109272 Comparator | Jan 2024 → Sep 2030 expected | hepatocellular carcinoma | AbbVie | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06840782 Background | Sep 2025 → Feb 2030 expected | non-small cell lung carcinoma | Gustave Roussy, Cancer Campus, Grand Paris | Recruiting | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-01 | AstraZeneca | Imfinzi plus Imjudo combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolisation-eligible unresectable liver cancer in EMERALD-3 Phase III trial astrazeneca.com ↗ |
| 2026-04-02 | AstraZeneca | Imfinzi plus Imjudo combined with lenvatinib and TACE demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in embolisation-eligible unresectable liver cancer in EMERALD-3 Phase III trial astrazeneca.com ↗ |
| 2024-09-16 | AstraZeneca | Imfinzi plus Imjudo demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial astrazeneca.com ↗ |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 264 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tremelimumab | “This is a single arm phase II study, in which 2 cycles of chemotherapy (5FU/CDDP) and immunotherapy (durvalumab and tremelimumab) are administered every 3 weeks with concurrent...” NCT03377400 ↗241“CP-675,206 (tremelimumab) is a fully humanized monoclonal antibody that binds to activated T lymphocytes and by enhancing their activation may produce a stimulation of the...” NCT01008358 ↗ “Tremelimumab (CP-675,206) is a fully human monoclonal antibody binding to cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) on T cells that stimulates the immune system by...” PMID 24907635 ↗ Jun 2014 “combinations such as atezolizumab plus bevacizumab, tremelimumab plus durvalumab, or monotherapies such as lenvatinib, sorafenib, tislelizumab, durvalumab, or pembrolizumab, at...” NCT06841172 ↗ “The first cohort patients will receive tremelimumab (3 mg/kg, single infusion) as immune-attractants combined with exemestane (25 mg daily).” NCT02997995 ↗ “Neoadjuvant Anti-PD-L1 (Durvalumab/MEDI4736) Plus Anti-CTLA-4 (Tremelimumab) and Radiation for High Risk Soft-Tissue Sarcoma” NCT03116529 ↗ “Tremelimumab is an antibody that targets cytotoxic T cell lymphocyte-associated protein 4 (CTLA4) on regulatory T cells.” NCT04989218 ↗ “STRIDE regimen of Single Tremelimumab (high, priming 300-mg dose) Regular Interval Durvalumab (1500 mg every 4 weeks)” NCT06364007 ↗ “Other alternatives include nivolumab-ipilimumab-chemotherapy or durvalumab-tremelimumab-chemotherapy association.” NCT06840782 ↗ “Patients will receive Durvalumumab + Tremelimumab if Bevacizumab is contraindicated.” NCT05620771 ↗ “receive one infusion of Durvalumab (1500mg IV) / Tremelimumab 300mg IV) on Day 15.” NCT07027436 ↗ “tremelimumab (formerly CP-675,206) at 10 mg/kg monthly” PMID 18452610 ↗ May 2008 “PD1 monoclonal antibody (Tremelimumab):” NCT05928962 ↗ |
| Known as | Bacille Calmette-Guérin (BCG) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04537663 ↗ |
| Known as | BCG vaccine | “licensed BCG vaccine (Danish strain 1331, SSI, Denmark)” NCT04537663 ↗ |
| Known as | CP-675 | “CP-675” NCT03618134 ↗ |
| Known as | CP-675,206 | “CP-675,206 (tremelimumab) is a fully humanized monoclonal antibody that binds to activated T lymphocytes and by enhancing their activation may produce a stimulation of the...” NCT01008358 ↗21“Tremelimumab (CP-675,206) is a fully human monoclonal antibody binding to cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) on T cells that stimulates the immune system by...” PMID 24907635 ↗ Jun 2014 “OUTLINE: This is an open-label, dose-escalation study of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody (CTLA4-blocking monoclonal antibody; CP-675,206).” NCT00090896 ↗ “Patients receive ticilimumab (CP-675,206) IV over 2 hours on day 1.” NCT00471887 ↗ “Anti-CTLA4 monoclonal antibody (CP-675,206)” NCT00610857 ↗ “CP-675,206 (Tremelimumab)” NCT00378482 ↗ “CP-675206” NCT03618134 ↗ |
| Known as | Imjudo | “the FDA approved tremelimumab (Imjudo) in combination with durvalumab for adult patients with unresectable hepatocellular carcinoma.” PMID 37676259 ↗ Jan 20241“Durvalumab (Imfinzi®) With Tremelimumab (Imjudo®)” NCT05063565 ↗ |
| Known as | Ticilimumab | “Patients receive ticilimumab (CP-675,206) IV over 2 hours on day 1.” NCT00471887 ↗ |
| Known as | treme | “tremelimumab (treme), an IgG2 monoclonal antibody blocking cytotoxic T-lymphocyte-associated protein- (CTLA-4)” PMID 34772758 ↗ Nov 20211“Drug: tremelimumab (treme)” NCT02499328 ↗ |
| Action | Inhibit | “CTLA4-blocking antibody tremelimumab” PMID 18452610 ↗ May 2008 |
| Modality | Monoclonal antibody | “monoclonal antibody tremelimumab” PMID 18452610 ↗ May 2008 |
| Route | Intravenous | “Patients receive CP-675,206 IV” NCT00090896 ↗ |
| Target | CTLA4 | “CTLA4-blocking antibody tremelimumab” PMID 18452610 ↗ May 2008 |